Get Newsletter
Alzheimer Research Forum - Networking for a Cure Alzheimer Research Forum - Networking for a CureAlzheimer Research Forum - Networking for a Cure
  
What's New HomeContact UsHow to CiteGet NewsletterBecome a MemberLogin          
Papers of the Week
Current Papers
ARF Recommends
Milestone Papers
Search All Papers
Search Comments
News
Research News
Drug News
Conference News
Research
AD Hypotheses
  AlzSWAN
  Current Hypotheses
  Hypothesis Factory
Forums
  Live Discussions
  Virtual Conferences
  Interviews
Enabling Technologies
  Workshops
  Research Tools
Compendia
  AlzGene
  AlzRisk
  Antibodies
  Biomarkers
  Mutations
  Protocols
  Research Models
  Video Gallery
Resources
  Bulletin Boards
  Conference Calendar
  Grants
  Jobs
Early-Onset Familial AD
Overview
Diagnosis/Genetics
Research
News
Profiles
Clinics
Drug Development
Companies
Tutorial
Drugs in Clinical Trials
Disease Management
About Alzheimer's
  FAQs
Diagnosis
  Clinical Guidelines
  Tests
  Brain Banks
Treatment
  Drugs and Therapies
Caregiving
  Patient Care
  Support Directory
  AD Experiences
Community
Member Directory
Researcher Profiles
Institutes and Labs
About the Site
Mission
ARF Team
ARF Awards
Advisory Board
Sponsors
Partnerships
Fan Mail
Support Us
Return to Top
Home: News
News
News Search  
Recasting Nicastrin as Substrate Snare
23 May 2012. Nicastrin is one of four proteins in the γ-secretase complex but other than that, precious little is known about exactly what it does. Some studies claim that its sole job is to promote formation of the complex. Others suggest that in the secretase’s processing of amyloid precursor protein (APP) and other transmembrane fodder, nicastrin binds substrates. Now, new evidence lends support to the substrate-binding argument. In the May 14 Proceedings of the National Academy of Sciences, Sangram Sisodia, University of Chicago, Illinois, and colleagues describe how they stumbled upon a nicastrin domain that seems to control substrate binding, which would make two found so far.

"There hasn't been any synthesis of opinion in the field about what nicastrin does," said Sisodia. While his results do not settle the matter, "people might be swayed by the evidence in favor of a role of nicastrin in substrate binding," he told Alzforum.

γ-Secretase comprises nicastrin, presenilin (PS1 or PS2), presenilin enhancer 2 (better known as Pen-2), and anterior pharynx-defective 1 (Aph-1). The complex cuts APP C-terminal fragments into Aβ. It also processes a slew of other proteins, including Notch, which is essential for development. How γ-secretase recognizes its substrates remains unclear, though in 2005, Gang Yu, University of Texas Southwestern Medical Center, Dallas, and colleagues suggested that was nicastrin's role (see ARF related news story). For this proposed function, the group identified a nicastrin ectodomain region they named the DAP domain. Alas, later studies implied that nicastrin plays no part in substrate recognition (see ARF related news story on Zhao et al., 2010), suggesting instead that nicastrin helped assemble the γ-secretase complex (see Chávez-Gutiérrez et al., 2008).

To settle the matter, first author Xulun Zhang and colleagues raised antibodies that would bind and stabilize nicastrin for crystallization. Some fit the bill. One, Fab2, bound to the nicastrin ectodomain region that lies on the C-terminal side of the DAP domain. Fab2 blocked γ-secretase activity in a test tube, which the authors took to mean that the bound area was necessary for γ-secretase function. Using a database search, Zhang found that the Fab2 binding site is homologous to the previously described tetratricopeptide repeat (TPR) domain that is important for other protein-protein interactions (see D'Andrea and Regan, 2003). "That gave us even more incentive to pursue this domain, because we thought we could identify important residues needed for substrate binding," said Sisodia.

To see if this TPR domain bound γ-secretase substrates, the researchers mutated two amino acids within the region predicted to be important for protein binding. One of those mutations suppressed Notch processing. Several others also disrupted cleavage, but none prevented γ-secretase complex formation, confirming for the authors that the TPR-like region functions in peptide binding.

"As a whole, this is very interesting—a new motif in nicastrin has been identified that may be important for substrate recognition," said Michael Wolfe, Brigham and Women's Hospital, Boston, Massachusetts. There are other possible explanations for the results that give him pause and provide grounds for further study, Wolfe said. For instance, rather than binding to and specifically interfering with a domain necessary for substrate recognition, Fab2's size and position could have blocked γ-secretase activity. Sisodia acknowledged that it is a fair point, but noted that a similarly sized Fab12 antibody also bound nearby and did not block the enzyme's action.

The search for binding domains in nicastrin is important, because they could have different affinities for the complex’s various substrates, opening up new possibilities of differentially regulating those sites, said Yu. That could point to new therapeutic targets for AD that change the processing of APP while leaving Notch and other proteins alone. Several γ-secretase modulators, which are designed to do just that, are in various stages of clinical development (see ARF related news story). To date, a lot of effort has been put into manipulating presenilin, which does the actual cleaving, while nicastrin has taken a backseat, Yu said. "Nicastrin deserves to be looked at," he suggested. "I would argue that the best way to manage γ-secretase is to manipulate the mechanism that differentially recognizes all its different substrates."

Sisodia and his group are currently looking for more antibodies that bind nicastrin. They have found some that bind in the same domain as Fab2, but do not overlap with its epitope. "I would predict that there would be other synthetic antibodies that can bind to different domains of nicastrin," he said, some of which "could affect processing of one substrate versus another.”—Gwyneth Dickey Zakaib.

Reference:
Zhang X, Hoey RJ, Lin G, Koide A, Leung B, Ahn K, Dolios G, Paduch M, Ikeuchi T, Wang R, Li YM, Koide S, Sisodia SS. Identification of a tetratricopeptide repeat-like domain in the nicastrin subunit of γ-secretase using synthetic antibodies. Proc Natl Acad Sci U S A. 2012 May 14. Abstract

 
Comments on News and Primary Papers
  Primary Papers: Identification of a tetratricopeptide repeat-like domain in the nicastrin subunit of γ-secretase using synthetic antibodies.

Comment by:  Lucia Chavez-Gutierrez, Bart De Strooper, ARF Advisor
Submitted 31 May 2012  |  Permalink Posted 31 May 2012

We read with great interest the manuscript of Zhang et al. They provide preliminary evidence for a predicted novel peptide-binding region in the ectodomain of nicastrin (Nct), which could have a potential role in substrate recruitment to the γ-secretase complex.

We would like to comment on a few specific points in the manuscript:

1. While the inhibitory effect of the anti-Nct antibody and the mutagenesis data provide evidence for the involvement of Nct ectodomain in γ-secretase activity and suggest a possible role for Nct in substrate recruitment, alternative interpretations, such as steric hindrance caused by the binding of the antibody or effects on the overall conformation of the complex, are also possible, and have not been excluded or discussed in this study. As the authors point out, it is likely that only crystallization studies will provide a definitive answer to this question, and, in fact, we completely agree with this conclusion.

2. In our previous study, we proposed that the nicastrin ectodomain was necessary for maturation of γ-secretase, but not for...  Read more

  Submit a Comment on this News Article
Cast your vote and/or make a comment on this news article. 

If you already are a member, please login.
Not sure if you are a member? Search our member database.

*First Name  
*Last Name  
Country or Territory:
*Login Email Address  
*Password    Minimum of 8 characters
*Confirm Password  
Stay signed in?  

I recommend the Primary Papers

Comment:

(If coauthors exist for this comment, please enter their names and email addresses at the end of the comment.)

References:


*Enter the verification code you see in the picture below:


This helps Alzforum prevent automated registrations.

Terms and Conditions of Use:Printable Version

By clicking on the 'I accept' below, you are agreeing to the Terms and Conditions of Use above.
Print this page
Email this page
Alzforum News
Papers of the Week
Text size
Share & Bookmark
ADNI Related Links
ADNI Data at LONI
ADNI Information
DIAN
Foundation for the NIH
AddNeuroMed
neuGRID
Desperately

Antibodies
Cell Lines
Collaborators
Papers
Research Participants
Copyright © 1996-2013 Alzheimer Research Forum Terms of Use How to Cite Privacy Policy Disclaimer Disclosure Copyright
wma logoadadad